Back to search results

ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Recurrent Diffuse Large B-Cell Lymphoma · Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified · Recurrent Grade 3b Follicular Lymphoma · Recurrent High-Grade B-Cell Lymphoma · Recurrent Indolent B-Cell Non-Hodgkin Lymphoma · Recurrent Primary Mediastinal Large B-Cell Lymphoma · Refractory Diffuse Large B-Cell Lymphoma · Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified · Refractory Grade 3b Follicular Lymphoma · Refractory High-Grade B-Cell Lymphoma · Refractory Indolent B-Cell Non-Hodgkin Lymphoma · Refractory Primary Mediastinal Large B-Cell Lymphoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

    Contact: Study coordinator (Immunotherapy Intake Coordinator) · immunotherapy@fredhutch.org · 206-606-4668
    Contact: Principal Investigator (Alexandre V. Hirayama, MD)
Study leads

  • Alexandre V. Hirayama, MD

    Principal Investigator

    Fred Hutch/University of Washington Cancer Consortium

View source on ClinicalTrials.gov(opens in a new tab)